Breaking News Bar
updated: 4/8/2014 3:19 PM

CVS settles SEC investigation for $20 million

hello
Success - Article sent! close
  • CVS Caremark has finalized a $20 million settlement with the Securities and Exchange Commission over accusations that the company misled investors and used improper accounting to boost its performance several years ago. CVS has mail order and tech operations in Mount Prospect, Northbrook, Bannockburn and Linconshire.

      CVS Caremark has finalized a $20 million settlement with the Securities and Exchange Commission over accusations that the company misled investors and used improper accounting to boost its performance several years ago. CVS has mail order and tech operations in Mount Prospect, Northbrook, Bannockburn and Linconshire.
    Associated Press

 
Associated Press

CVS Caremark has finalized a $20 million settlement with the Securities and Exchange Commission over accusations that the company misled investors and used improper accounting to boost its performance several years ago.

CVS has mail order and tech operations in Mount Prospect, Northbrook, Bannockburn and Linconshire.

Order Reprint Print Article
 
Interested in reusing this article?
Custom reprints are a powerful and strategic way to share your article with customers, employees and prospects.
The YGS Group provides digital and printed reprint services for Daily Herald. Complete the form to the right and a reprint consultant will contact you to discuss how you can reuse this article.
Need more information about reprints? Visit our Reprints Section for more details.

Contact information ( * required )

Success - request sent close

The drugstore chain and pharmacy benefits manager had announced the settlement last August, when it also said it neither admitted nor denied anything in reaching the agreement.

The SEC accused CVS Caremark of misleading investors by failing to report in 2009 bond offering documents that it had recently lost significant contract revenues in its pharmacy benefits management business, which process mail-order prescriptions and runs drug plans for employers and other clients.

The regulator said that misled investors about future results from that segment.

"CVS broke faith with investors in both its stock and its bonds by disguising significant setbacks for its pharmacy benefits management business," said Andrew Ceresney, director of the SEC's enforcement division, in a statement.

CVS Caremark Corp. also runs the nation's second-largest drugstore chain, behind Walgreen Co. The SEC also said CVS made improper accounting adjustments that overstated results from that business during the same time frame.

CVS executive Laird Daniels has agreed to pay a $75,000 penalty and will be barred for at least a year from practicing as an accountant for any publicly traded company or entity regulated by the SEC, the agency said.

Daniels is senior vice president of international operations and business development for the company.

The Woonsocket, R.I., company said Tuesday that the matter is now fully resolved. It had said in August it wouldn't have to restate earnings, and it had already set aside money for the penalty.

Share this page
Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.